SG10201906172XA - Regulation of glucose metabolism using anti-cgrp antibodies - Google Patents
Regulation of glucose metabolism using anti-cgrp antibodiesInfo
- Publication number
- SG10201906172XA SG10201906172XA SG10201906172XA SG10201906172XA SG10201906172XA SG 10201906172X A SG10201906172X A SG 10201906172XA SG 10201906172X A SG10201906172X A SG 10201906172XA SG 10201906172X A SG10201906172X A SG 10201906172XA SG 10201906172X A SG10201906172X A SG 10201906172XA
- Authority
- SG
- Singapore
- Prior art keywords
- regulation
- glucose metabolism
- cgrp antibodies
- cgrp
- optionally
- Prior art date
Links
- 230000029964 regulation of glucose metabolic process Effects 0.000 title abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 230000002440 hepatic effect Effects 0.000 abstract 2
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
Abstract
REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance. (Figure 1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842745P | 2013-07-03 | 2013-07-03 | |
| US201461982611P | 2014-04-22 | 2014-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201906172XA true SG10201906172XA (en) | 2019-08-27 |
Family
ID=52144290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201906172XA SG10201906172XA (en) | 2013-07-03 | 2014-07-03 | Regulation of glucose metabolism using anti-cgrp antibodies |
| SG11201510618YA SG11201510618YA (en) | 2013-07-03 | 2014-07-03 | Regulation of glucose metabolism using anti-cgrp antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510618YA SG11201510618YA (en) | 2013-07-03 | 2014-07-03 | Regulation of glucose metabolism using anti-cgrp antibodies |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150017166A1 (en) |
| EP (1) | EP3016684B1 (en) |
| JP (4) | JP6502337B2 (en) |
| KR (1) | KR102476907B1 (en) |
| CN (1) | CN105492026A (en) |
| AU (2) | AU2014285052B2 (en) |
| CA (1) | CA2916980C (en) |
| ES (1) | ES2911690T3 (en) |
| IL (1) | IL243355B1 (en) |
| MX (1) | MX2016000220A (en) |
| NZ (1) | NZ754427A (en) |
| SG (2) | SG10201906172XA (en) |
| TW (2) | TWI753471B (en) |
| WO (1) | WO2015003122A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201906172XA (en) * | 2013-07-03 | 2019-08-27 | Alder Biopharmaceuticals Inc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| RS65360B1 (en) | 2014-03-21 | 2024-04-30 | Teva Pharmaceuticals Int Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| SG10202003296VA (en) | 2020-04-06 | 2021-11-29 | H Lundbeck As | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
| CA3229059A1 (en) | 2021-08-27 | 2023-03-02 | H. Lundbeck A/S | Treatment of cluster headache using anti-cgrp antibodies |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| WO1989006135A1 (en) * | 1988-01-11 | 1989-07-13 | Amylin Corporation | Treatment of type 2 diabetes mellitus |
| US5266561A (en) * | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| US5364841A (en) * | 1988-01-11 | 1994-11-15 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and essential hypertension and related disorders |
| US5175145A (en) | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| WO1990007792A1 (en) * | 1989-01-03 | 1990-07-12 | Motorola, Inc. | Method of making high density solder bumps and a substrate socket for high density solder bumps |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| EP0408294B1 (en) * | 1989-07-10 | 1995-09-20 | Amylin Pharmaceuticals, Inc. | Use of an amylin antagonist for the manufacture of amedicament for the treatment of obesity and essential hypertension and related disorders |
| FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| EP0771208B1 (en) | 1994-08-12 | 2005-10-19 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| CA2471833A1 (en) * | 2001-11-26 | 2003-06-05 | Protemix Corporation Limited | Methods of compositions for normalizing lipid levels in mammalian tissues |
| ES2393555T3 (en) | 2003-10-22 | 2012-12-26 | Keck Graduate Institute | Methods for the synthesis of hetero-multimeric polypeptides in yeasts using a haploid mating strategy. |
| MX2008014692A (en) | 2006-05-19 | 2009-08-18 | Alder Biopharmaceuticals Inc | Culture method for obtaining a clonal population of antigen-specific b cells. |
| TWI561530B (en) | 2007-05-21 | 2016-12-11 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
| WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
| TWI609965B (en) | 2007-05-21 | 2018-01-01 | 艾爾德生物控股有限責任公司 | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| CN108359008B (en) * | 2011-05-20 | 2022-03-29 | H.伦德贝克公司 | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments for the treatment or prevention of chronic and acute forms of diarrhea |
| ES2873837T3 (en) * | 2011-05-20 | 2021-11-04 | H Lundbeck As | Anti CGRP compositions and their use |
| SG10201906172XA (en) * | 2013-07-03 | 2019-08-27 | Alder Biopharmaceuticals Inc | Regulation of glucose metabolism using anti-cgrp antibodies |
-
2014
- 2014-07-03 SG SG10201906172XA patent/SG10201906172XA/en unknown
- 2014-07-03 CA CA2916980A patent/CA2916980C/en active Active
- 2014-07-03 AU AU2014285052A patent/AU2014285052B2/en active Active
- 2014-07-03 WO PCT/US2014/045389 patent/WO2015003122A2/en active Application Filing
- 2014-07-03 ES ES14820173T patent/ES2911690T3/en active Active
- 2014-07-03 EP EP14820173.4A patent/EP3016684B1/en active Active
- 2014-07-03 MX MX2016000220A patent/MX2016000220A/en active IP Right Grant
- 2014-07-03 TW TW109121891A patent/TWI753471B/en active
- 2014-07-03 IL IL243355A patent/IL243355B1/en unknown
- 2014-07-03 CN CN201480047723.5A patent/CN105492026A/en active Pending
- 2014-07-03 KR KR1020167002907A patent/KR102476907B1/en active IP Right Grant
- 2014-07-03 SG SG11201510618YA patent/SG11201510618YA/en unknown
- 2014-07-03 US US14/323,028 patent/US20150017166A1/en not_active Abandoned
- 2014-07-03 JP JP2016524371A patent/JP6502337B2/en active Active
- 2014-07-03 NZ NZ754427A patent/NZ754427A/en unknown
- 2014-07-03 TW TW103122993A patent/TWI712419B/en active
-
2018
- 2018-07-06 JP JP2018128766A patent/JP2018168186A/en not_active Withdrawn
-
2019
- 2019-03-20 JP JP2019052046A patent/JP2019112455A/en active Pending
- 2019-12-10 AU AU2019279945A patent/AU2019279945B2/en active Active
-
2020
- 2020-06-17 JP JP2020104177A patent/JP2020158525A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014285052A1 (en) | 2016-02-11 |
| JP6502337B2 (en) | 2019-04-17 |
| MX2016000220A (en) | 2016-08-18 |
| TW201536316A (en) | 2015-10-01 |
| ES2911690T3 (en) | 2022-05-20 |
| KR102476907B1 (en) | 2022-12-13 |
| EP3016684B1 (en) | 2022-02-23 |
| CA2916980A1 (en) | 2015-01-08 |
| IL243355A0 (en) | 2016-03-31 |
| KR20160029822A (en) | 2016-03-15 |
| IL243355B1 (en) | 2024-06-01 |
| AU2019279945B2 (en) | 2022-01-20 |
| CA2916980C (en) | 2023-02-21 |
| NZ715834A (en) | 2021-11-26 |
| AU2014285052B2 (en) | 2019-09-12 |
| TWI753471B (en) | 2022-01-21 |
| CN105492026A (en) | 2016-04-13 |
| SG11201510618YA (en) | 2016-03-30 |
| NZ754427A (en) | 2021-12-24 |
| WO2015003122A2 (en) | 2015-01-08 |
| EP3016684A2 (en) | 2016-05-11 |
| US20150017166A1 (en) | 2015-01-15 |
| TW202106335A (en) | 2021-02-16 |
| AU2019279945A1 (en) | 2020-01-16 |
| JP2018168186A (en) | 2018-11-01 |
| JP2019112455A (en) | 2019-07-11 |
| JP2016528198A (en) | 2016-09-15 |
| JP2020158525A (en) | 2020-10-01 |
| WO2015003122A3 (en) | 2015-03-19 |
| TWI712419B (en) | 2020-12-11 |
| EP3016684A4 (en) | 2017-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| PH12020500352A1 (en) | Therapeutic uses of empagliflozin | |
| BR112014032699A2 (en) | Pediatric metabolic syndrome treatment methods | |
| NZ626954A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
| MX2015013948A (en) | Therapeutic uses of empagliflozin. | |
| EA201490004A1 (en) | BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES | |
| MX2019001977A (en) | Methods and compositions for treating multiple sclerosis and related disorders. | |
| MX2015002289A (en) | Human antibodies to gfrî±3 and methods of use thereof. | |
| NZ719520A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| WO2009073544A3 (en) | Methods for treating a disorder by regulating gprc6a | |
| GEP20196969B (en) | New therapeutical composition containing apomorphine as active ingredient | |
| EA201491702A1 (en) | OPTIMIZED THERAPEUTIC AGENTS FOR SCRAPTURE INTRODUCTION | |
| BR112015010039A2 (en) | treatment of cancer with pomalidomide in an individual with renal dysfunction | |
| MX2015015036A (en) | Methods for improving lipid profiles using atrasentan. | |
| WO2014153385A3 (en) | Methods of treating metabolic disorders | |
| NZ720273A (en) | Preparations and methods for treating a gd2 positive cancer | |
| WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
| BR112014029308A2 (en) | a method of improving liver function | |
| WO2012044963A3 (en) | Perfluorocarbons for use in treating pruritus | |
| BR112017015840A2 (en) | Method of treating or preventing atherothrombotic events in patients with a history of myocardial infarction | |
| MX359686B (en) | Metadichol r liquid and gel nanoparticle formulations. | |
| MX2016013680A (en) | Methods and compositions for treatment of lipid storage disorders. | |
| WO2013188876A3 (en) | Methods for modulating kallikrein (klkb1) expression | |
| MX2014001271A (en) | Treatment of type 2 diabetes with fty720. |